Researcher at Independent, Chile
Dr. Rancés Blanco Santana is an accomplished Cuban researcher with extensive expertise in oncology, molecular biology, and histopathology. His work primarily focuses on understanding the interplay between oncogenic viruses such as Epstein-Barr Virus (EBV) and Human Papillomavirus (HPV) and their role in carcinogenesis, particularly in head and neck, cervical, and breast cancers. With a prolific publication record of over 30 peer-reviewed articles in high-impact journals, Dr. Blanco has significantly contributed to advancing knowledge in cancer biomarkers, therapeutic targets, and the mechanisms of environmental carcinogens. His career spans over 15 years of impactful research, including international collaborations and independent studies. He is currently based in Santiago, Chile, where he continues to lead cutting-edge cancer research. Dr. Blanco’s dedication to biomedical science, combined with his ability to address complex health challenges, establishes him as a leading figure in his field.
Professional profile
Education📚
Dr. Blanco Santana has a robust academic foundation in health sciences. He earned his Bachelor’s in Health Technology (specializing in Cytohistopathology) from the Higher Institute of Medical Sciences in Havana, Cuba, in 2007. He later obtained a Diploma in Histology from the Institute of Basic and Preclinical Sciences “Victoria de Girón” in 2008. His commitment to advancing his expertise culminated in earning a Ph.D. in Health Sciences from the University of Medical Sciences of Havana in 2017. These credentials underscore his deep theoretical and practical knowledge in cancer biology and histological techniques. His academic training has been instrumental in shaping his career as a researcher and in conducting translational studies that address critical issues in cancer diagnostics and treatment.
Professional Experience🏛️
Dr. Blanco’s career spans a diverse range of roles across esteemed institutions. Currently, he is an Independent Researcher in Santiago, Chile (2022–present). Previously, he was a Postdoctoral Research Assistant at the Laboratory of Molecular Oncovirology, University of Chile (2019–2022), where he focused on the molecular mechanisms of viral carcinogenesis. His earlier tenure at the Center of Molecular Immunology in Havana, Cuba, involved roles as a Postdoctoral Research Assistant (2017–2019), an Associate Researcher (2007–2017), and a Quality Control Specialist (2007–2019). These experiences highlight his expertise in cancer immunology, therapeutic antibody development, and quality control. His ability to adapt to multidisciplinary teams and environments has been a hallmark of his professional growth.
Research Interest🌐
Dr. Blanco’s research interests lie at the intersection of viral oncology and molecular carcinogenesis. He explores how oncogenic viruses like EBV and HPV interact with environmental factors, such as tobacco smoke, to drive cancer progression. His studies on co-infections in head and neck cancers, cervical lesions, and breast cancer have provided insights into the molecular pathways involved, including oxidative stress, DNA damage, and immune evasion. He is particularly interested in identifying biomarkers and novel therapeutic targets to improve cancer diagnosis and treatment. Dr. Blanco’s research also extends to the study of tumor microenvironments, monoclonal antibody therapies, and the role of oxidative stress sensors in epithelial malignancies, reflecting his commitment to addressing complex biomedical challenges.
Awards and Honors🏆
Although specific awards and honors are not explicitly detailed in the provided information, Dr. Blanco’s contributions to cancer research and his extensive publication record position him as a prominent researcher deserving of recognition. His achievements have likely earned him informal accolades and professional respect in his field. Notably, his selection for postdoctoral roles at prestigious institutions, such as the University of Chile, is a testament to his expertise and leadership in molecular oncology. Further acknowledgment of his work through formal awards would serve to highlight the significant impact of his research on cancer biology and therapeutic innovation.
Conclusion
Dr. Rancés Blanco Santana stands out as a strong candidate for the Best Researcher Award due to his profound contributions to oncology research, extensive publication record, and ability to work across disciplines and geographic regions. Enhancing his leadership profile and visibility in global scientific forums would further solidify his candidacy. Overall, his qualifications and achievements make him highly deserving of this recognition.
Publications top noted📜
- Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody
Authors: G. Garrido, A. Rabasa, B. Sánchez, M.V. López, R. Blanco, A. López, …
Year: 2011
Citations: 108
- Biological Activity In Vitro of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Affinities
Authors: A. Diaz Miqueli, R. Blanco, B. Garcia, T. Badia, A.E. Batista, R. Alonso, …
Year: 2007
Citations: 67
- Immunoreactivity of the 14F7 Mab (raised against N‐Glycolyl GM3 Ganglioside) as a positive prognostic factor in non‐small‐cell lung cancer
Authors: R. Blanco, C.E. Rengifo, M. Cedeno, M. Frometa, E. Rengifo, A. Carr
Year: 2012
Citations: 56
- Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system
Authors: R. Blanco, E. Rengifo, M. Cedeño, C.E. Rengifo, D.F. Alonso, A. Carr
Year: 2011
Citations: 52
- Prognostic significance of N‐glycolyl GM3 ganglioside expression in non‐small cell lung carcinoma patients: New evidences
Authors: R. Blanco, E. Domínguez, O. Morales, D. Blanco, D. Martínez, C.E. Rengifo, …
Year: 2015
Citations: 45
- Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N‐Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms
Authors: R. Blanco, E. Rengifo, C.E. Rengifo, M. Cedeno, M. Frometa, A. Carr
Year: 2011
Citations: 41
- High-risk human papillomavirus and tobacco smoke interactions in epithelial carcinogenesis
Authors: F. Aguayo, J.P. Muñoz, F. Perez-Dominguez, D. Carrillo-Beltrán, C. Oliva, …
Year: 2020
Citations: 38
- Human antibodies reactive to NeuGc GM3 ganglioside have cytotoxic antitumor properties
Authors: N. Rodríguez‐Zhurbenko, D. Martínez, R. Blanco, T. Rondón, T. Griñán, …
Year: 2013
Citations: 37
- Tissue Reactivity of the 14F7 Mab Raised against N‐Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin
Authors: R. Blanco, Y. Quintana, D. Blanco, M. Cedeño, C.E. Rengifo, M. Frómeta, …
Year: 2013
Citations: 29
- Role of Epstein-Barr virus and human papillomavirus coinfection in cervical cancer: epidemiology, mechanisms and perspectives
Authors: R. Blanco, D. Carrillo-Beltrán, J.C. Osorio, G.M. Calaf, F. Aguayo
Year: 2020
Citations: 26
- Role of Pirin, an Oxidative Stress Sensor Protein, in Epithelial Carcinogenesis
Authors: A.F. Perez-Dominguez, D. Carrillo-Beltrán, R. Blanco, J.P. Muñoz, G. León-Cruz, …
Year: 2021
Citations: 24
- Immunoreactivity of the 14F7 Mab Raised against N‐Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis
Authors: R. Blanco, D. Blanco, Y. Quintana, X. Escobar, C.E. Rengifo, M. Osorio, …
Year: 2013
Citations: 24
- Immunorecognition of the 14F7 Mab Raised against N‐Glycolyl GM3 Ganglioside in Some Normal and Malignant Tissues from Genitourinary System
Authors: R. Blanco, M. Cedeño, X. Escobar, D. Blanco, C.E. Rengifo, M. Frómeta, …
Year: 2011
Citations: 24
- High-Risk Human Papillomavirus and Epstein–Barr Virus Coinfection: A Potential Role in Head and Neck Carcinogenesis
Authors: R. Blanco, D. Carrillo-Beltrán, A.H. Corvalán, F. Aguayo
Year: 2021
Citations: 23
- Human papillomavirus 16 E7 promotes EGFR/PI3K/AKT1/NRF2 signaling pathway contributing to PIR/NF-κB activation in oral cancer cells
Authors: D. Carrillo-Beltrán, J.P. Muñoz, N. Guerrero-Vásquez, R. Blanco, O. León, …
Year: 2020
Citations: 23
